23andMe, Inc.

This docket consolidates claims arising from a 2023 data security breach at 23andMe, the consumer genetic-testing company, in which attackers used credential-stuffing techniques to access a subset of user accounts and then leveraged 23andMe's relative-matching features to expose genetic and genealogical data belonging to a much larger number of users connected to the compromised accounts. Centralized in the Northern District of California, the docket carries 41 pending actions, addressing a claim category involving an unusually sensitive category of exposed data: genetic and ancestry information.

For a funder, the sensitivity of genetic data is a distinguishing underwriting consideration relative to more conventional data-breach litigation involving financial or contact information — claims here may support damages theories tied to the unique, immutable, and family-implicating nature of genetic data, which several courts and commentators have treated as raising distinct privacy concerns. Diligence should also account for the breach's relative-matching mechanism, since many affected individuals were exposed not because their own account was directly compromised but because a genetically related user's account was.

As a data-privacy matter, medical-lien considerations do not apply notwithstanding the health-adjacent nature of genetic information. For a claimant group or firm with claims tied to this breach, Criterica Capital's commercial litigation finance line is the applicable structure, with diligence focused on whether the claimant was a directly compromised account holder or was exposed through the relative-matching feature, since that distinction may affect the applicable damages theory. A structural brief on this docket is available through Criterica Intelligence.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.